Cyfuse Biomedical KKTSE:4892 +2.99%53 Quick Ratio is 4.44 as of Dec. 2025, which is 28% below its 10-year median of 6.19. GuruFocus rates TSE:4892 with a GF Score™ of 53/100 and a GF Value™ of 円2,179.63 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 999 Drug Manufacturers companies, Cyfuse Biomedical KK ranks better than 87.29% on this metric.
Cyfuse Biomedical KK has a quick ratio of 4.44. It generally indicates good short-term financial strength.
The historical rank and industry rank for Cyfuse Biomedical KK's Quick Ratio or its related term are showing as below:
TSE:4892'
s Quick Ratio Range Over the Past 10 Years
Min: 4.44 Med: 6.19 Max: 10.29
Current: 4.44
During the past 6 years, Cyfuse Biomedical KK's highest Quick Ratio was 10.29. The lowest was 4.44. And the median was 6.19.
TSE:4892's Quick Ratio is ranked better than 87.29% of 999
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs TSE:4892: 4.44
Cyfuse Biomedical KK (TSE:4892) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Cyfuse Biomedical KK Quick Ratio Related Terms
Cyfuse Biomedical KK Quick Ratio Historical Data
* Premium members only.
The historical data trend for Cyfuse Biomedical KK's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cyfuse Biomedical KK's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyfuse Biomedical KK Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cyfuse Biomedical KK's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Cyfuse Biomedical KK's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Cyfuse Biomedical KK's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyfuse Biomedical KK (TSE:4892) has a Quick Ratio of 4.44 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Cyfuse Biomedical KK and its competitors. This is 28% below median its historical median of 6.19. Over the past decade, Cyfuse Biomedical KK's Quick Ratio has ranged from 4.44 to 10.29. According to the industry distribution chart, Cyfuse Biomedical KK ranks #127 out of 999 companies in the Drug Manufacturers industry, placing it in the top 12.7%.
Is Cyfuse Biomedical KK's Quick Ratio too high?
Cyfuse Biomedical KK's current Quick Ratio of 4.44 is 28% below median its 10-year median of 6.19. Over the past 10 years, this metric has ranged from a low of 4.44 to a high of 10.29. The Drug Manufacturers industry median Quick Ratio is 1.45. Cyfuse Biomedical KK's value of 4.44 is 206.2% above this industry median. Based on the distribution chart, Cyfuse Biomedical KK ranks #127 out of 999 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cyfuse Biomedical KK has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyfuse Biomedical KK's Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cyfuse Biomedical KK ranks #127 out of 999 companies for Quick Ratio. This places Cyfuse Biomedical KK in the top 13% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.45. Cyfuse Biomedical KK's value of 4.44 is 206.2% above this benchmark. Historically, Cyfuse Biomedical KK's own Quick Ratio has ranged from 4.44 to 10.29 over the past decade. While the company's 10-year median is 6.19 vs. the industry median of 1.45, Cyfuse Biomedical KK has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 999 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cyfuse Biomedical KK's current Quick Ratio of 4.44 is 206.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Cyfuse Biomedical KK and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyfuse Biomedical KK's current Quick Ratio is 4.44, which is 28% below median its own 10-year median of 6.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyfuse Biomedical KK stock overvalued right now?
Based on GuruFocus' analysis, Cyfuse Biomedical KK (TSE:4892) is currently considered Possible Value Trap. The stock's GF Value™ is 円2,179.63, compared to a current price of 円552.00 — trading 74.7% below its estimated fair value. The current Quick Ratio is 4.44, which is 28% below median its 10-year median of 6.19 and 206.2% above the Drug Manufacturers industry median of 1.45. Cyfuse Biomedical KK's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Cyfuse Biomedical KK (TSE:4892), the current Quick Ratio is 4.44 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyfuse Biomedical KK (TSE:4892) Overvalued in 2026?
Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued.
The current stock price of 円552.00 is trading 74.7% below its estimated GF Value™ of 円2,179.63.
GuruFocus considers Cyfuse Biomedical KK to be Possible Value Trap.
Key valuation signals for TSE:4892:
Quick Ratio: 4.44 (28% below median its 10-year median of 6.19)
GF Value™: 円2,179.63 vs. price of 円552.00 (74.7% below fair value)
Industry Position: 206.2% above the Drug Manufacturers median (#127 of 999)
No single metric tells the full story. See the TSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
53GF Score
Get the complete analysis for TSE:4892
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4892 has been successfully added to your 
